



AMERISE BIOSCIENCES LIMITED

CIN: L29199GJ1984PLC007195

(Formerly Known as AMRADEEP INDUSTRIES LIMITED)

Date: 30.10.2026

To,
Department of Corporate Services
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Dear Sir / Madam,

Scrip Code: 531681

Security ID: AMERISE

Subject: Outcome of Board Meeting held on 30th October 2026.

Ref: Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. **Friday 30th October 2026**. at the Registered Office of the Company and transacted the following major businesses:

- 1.) Considered and approved Un-audited financial results for the quarter and half year ended as on 30th September, 2026.

The board meeting commented at **03:45 PM** and concluded at **04:15 PM**

Please take the above intimation in your records.

Thanking You,

Yours Faithfully,
For, Amerise Biosciences Limited

HINES ALBERT Digitally signed by HINES
ALBERT
Date: 2026.10.30 16:34:09
+05'30'

ALBERT HINES
Whole-time Director
DIN: 10742692

Amerise Biosciences Limited

CIN:-L29199GJ1984PLC007195

Regd. Office: 24, Laxmi Chambers, Navjeevan Press Road, Opp. Old Gujarat High Court, Ahmedabad - 380014

Email:- amradeepindustries@gmail.com

Statement of Audited Financial Results for the Quarter & Half Year Ended September 30, 2026

Sl no.	Particulars	Quarter Ended			Six Months Ended		(Rs. In lacs)
		30-Sep-26	30-Jun-26	30-Sep-25	30-Sep-26	30-Sep-25	Year Ended 31 Mar 2026
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	INCOME						
(a)	Revenue From Operation	-	-	-	-	-	-
(b)	Other Income	-	-	6.75	-	13.11	25.52
	Total Income from Operations (Net)	-	-	6.75	-	13.11	25.52
2	EXPENSES						
(a)	Cost of material consumed	-	-	-	-	-	-
(b)	Changes in inventories of finished goods, work-in-progress, and stock-in-trade	-	-	-	-	-	-
(c)	Employee benefit expense	0.82	0.94	1.80	1.76	4.12	7.37
(d)	Finance Costs	-	-	-	-	-	-
(e)	Depreciation and amortization expense	-	-	-	-	-	-
(f)	Other expenses(Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	4.94	7.21	9.18	12.15	14.03	16.09
	Total Expenses	5.76	8.14	10.98	13.91	18.15	23.46
3	Profit / (Loss) from operations before exceptional items Tax (1-2)	(5.76)	(8.14)	(4.23)	(13.91)	(5.04)	2.06
4	Exceptional Items	-	-	-	-	-	-
5	Profit / (Loss) before Tax (3 ± 4)	(5.76)	(8.14)	(4.23)	(13.91)	(5.04)	2.06
6	Tax Expense	-	-	-	-	-	0.45
7	Net Profit / (Loss) after Tax (5 - 6)	(5.76)	(8.14)	(4.23)	(13.91)	(5.04)	1.61
8	Other Comprehensive Income (net of tax)	-	-	-	-	-	-
9	Total Comprehensive Income for the period (7 ± 8)	(5.76)	(8.14)	(4.23)	(13.91)	(5.04)	1.61
10	Paid-up equity share capital (Face Value of Rs.1/- each)	660.69	660.69	660.69	660.69	660.69	660.69
11	Other Equity	-	-	-	-	-	(121.10)
12	Earnings Per Share (of Rs. 1/- each) (not annualised):						
	(a) Basic	(0.01)	(0.01)	(0.01)	(0.02)	(0.01)	0.00
	(b) Diluted	(0.01)	(0.01)	(0.01)	(0.02)	(0.01)	0.00

Amerise Biosciences Limited

CIN:-L29199GJ1984PLC007195

Regd. Office: 24, Laxmi Chambers, Navjeevan Press Road, Opp. Old Gujarat High Court, Ahmedabad - 380014

Email:- amradeepindustries@gmail.com

(Rs. in Lakhs)

Standalone Statement of Assets and Liabilities		As at 30th September, 2026	As at 31st March, 2026
	Particulars	Un-Audited	Audited
A	ASSETS		
1	Non-current assets		
	Property, plant and equipment	-	-
	Capital work-in-progress	-	-
	Other intangible assets	-	-
	Investments in subsidiaries, associates and joint ventures	-	-
	Financial assets		
	Investments	376.75	376.97
	Loans	300.20	304.03
	Other financial assets	-	-
	Income Tax assets (net)	-	-
	Deferred tax assets (net)	-	-
	Other non-current assets	-	-
	Sub-total - Non-Current Assets	676.95	681.00
2	Current assets		
	Inventories	-	-
	Financial assets	-	-
	Investments	-	-
	Trade receivables	-	-
	Cash and cash equivalents	2.46	59.19
	Bank balances other than Cash and Cash equivalents above	-	-
	Loans, Current	-	-
	Other financial assets	-	-
	Other current assets	2.00	2.00
	Assets classified as held for sale	-	-
	Sub-total - Current Assets	4.46	61.19
	TOTAL - ASSETS	681.41	742.19
B	EQUITY AND LIABILITIES		
1	Equity		
	Equity Share capital	660.69	660.69
	Other equity	(135.01)	(121.10)
	Sub-total - Shareholders' funds	525.68	539.59
2	LIABILITIES		
	Non-current liabilities		
	Financial liabilities		
	Borrowings, non-Current	-	-
	Provisions	-	-
	Income tax liabilities (net)	-	-
	Other non-current liabilities	-	-
	Sub-total - Non-current liabilities	-	-
3	Current liabilities		
	Financial liabilities		
	Borrowings, Current	3.00	-
	Trade payables, Current	-	-
	Other financial liabilities	152.00	202.00
	Other current liabilities	0.27	0.15
	Provisions	0.45	0.45
	Current tax liabilities (net)	-	-
	Sub-total - Current liabilities	155.72	202.60
	TOTAL - EQUITY AND LIABILITIES	681.41	742.19

Amerise Biosciences Limited

CIN:-L29199GJ1984PLC007195

Regd. Office: 24, Laxmi Chambers, Navjeevan Press Road, Opp. Old Gujarat High Court, Ahmedabad - 380014

Email:- amradeepindustries@gmail.com

Notes:

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on October 30, 2026.
- 2 The Statutory Auditors have carried out a limited review of the above financial result.
- 3 Company has only one segment and hence no separate segment result has been given.
- 4 The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.
- 5 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

By order of the Board
For, Amerise Biosciences Limited

HINES ALBERT Digitally signed by HINES ALBERT
Date: 2026.10.30 16:34:51 +05'30'

Place : , Ahmedabad
Date : 30th October, 2026

Albert Hines
Wholetime Director

Amerise Biosciences Limited

CIN:-L29199GJ1984PLC007195

Regd. Office: 24, Laxmi Chambers, Navjeevan Press Road, Opp. Old Gujarat High Court, Ahmedabad - 380014

Email:- amradeepindustries@gmail.com

(Rs. in Lakhs, unless otherwise stated)

Particulars	30.09.2026	30.09.2025
	Rupees	Rupees
A. CASH FLOW FROM OPERATING ACTIVITIES:		
Profit before tax	- 13.91	- 5.04
Adjustment For :		
Share of (profit)/loss from investment in partnership firm	-	-
Depreciation/amortization on continuing operation	-	-
Interest expenses	-	-
Operating profit before working capital changes	- 13.91	- 5.04
Movement in Working Capital :		
Increase/(decrease) in Inventory	-	-
Increase/(decrease) in Trade receivables	-	-
Increase/(decrease) in Short Term Loan & Advances	-	-
Increase/(decrease) in Current Liabilities	- 49.88	- 1.98
Increase/(decrease) in Trade Payable	-	-
Increase/(decrease) in Other Current Assets	0.00	-
Direct taxes paid (net of refunds)		-
Net Cash Flow from Operating Activities(A)	- 63.78	- 7.02
B. CASH FLOW FROM INVESTING ACTIVITIES		
Investments / withdrawl in Partnership Firm	0.22	- 138.87
Purchase / Sale of Fixed Assets	-	-
Increase/(decrease) in Long Term Loan & Advances	3.83	146.05
Net Cash Flow from Investing Activities(B)	4.05	7.18
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceed (Repayment) from long term borrowing	-	-
Proceed (Repayment) from short term borrowing	3.00	-
Proceed from Preferential Warrants	-	-
Net Cash Flow from Financing Activities(C)	3.00	-
Net increase/(decrease) in cash & cash equivalents(A+B+C)	- 56.73	0.16
Cash and Cash equivalents (Opening Balance)	59.19	2.22
Cash and Cash equivalents (Closing Balance)	2.46	2.38

Previous year figure have been regrouped/ reclassified wherever necessary

As per our report of even date

For, Bipin & Co.

Chartered Accountants

SD

CA Amit Shah

Partner

M. No.: 126337

Place: Vadodara

Date : 30th October, 2026

For and on Behalf of the Board

**HINES
ALBERT**

Digitally signed by
HINES ALBERT
Date: 2026.10.30
16:35:43 +05'30'

Albert Hines

Wholetime Director

Place: Ahmedabad

Date : 30th October, 2026




Limited Review Report on Unaudited Standalone Financial Results of **Amerise Biosciences Limited** for the quarter and half year ended September 30, 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Amerise Biosciences Limited

1. We have reviewed the accompanying statement of unaudited Standalone financial results of **Amerise Biosciences Limited** for the quarter and half year ended September 30, 2026 ("the Statement") being submitted pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (Listing Regulations).
2. This Statement, which is the responsibility of the management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Financial Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain limited assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and is substantially less than the audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards, i.e. Ind AS 34 as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies, has not disclosed the Information required to be disclosed in terms of Regulation 33 of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, of that it contains any material misstatement.

For, BIPIN & CO.
Chartered Accountants
FRN: 101509 W


CA AMIT SHAH
Partner
M. No.: 126337
Place: Vadodara
Date: 30.10.2026
UDIN: 261263370QVKYH1568

